EGFR and neoplasm: Lacking of tissue sample is a significant limitation, even in prospectively conducted clinical trials, less than 50% of the patients had sufficient tumor tissues available for EGFR mutations analyses.[5] Interest has been stimulated in EGFR mutations analyses using surrogate samples such as blood.